Home » Newsletters » BioWorld

BioWorld

April 14, 1992

View Archived Issues

ROBERTS LICENSES PEDIATRIC DRUG FROM ORTHO

ENZON REPORTS ON BLOOD SUBSTITUTE

EPIGEN ARRANGES VEHICLE FOR CLINICAL TEST

DYNAGEN TO BEGIN PHASE II OF NICERASE

GOTTESMAN TAKES OVER GENOME PROJECT

BIOCHEM PHARMA OFFERING 3.5 MILLION SHARES

INVESTOR TO BUY TECHNICLONE SHARES

ROCHE LICENSES COMPOUNDS FROM XENOVA

ALKERMES LAUNCHES PARTNERSHIP FOR $46M

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026